Year 2016: top* 10 papers with the highest R-portion

Topic: Cancer Immunotherapy

* The top 5% of entries has been removed to reduce statistical anomalies. Further fine-tuning, filtering, and error cleaning are in progress.

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

YCR = 2016 / 546 /  17.27 

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

YCR = 2016 / 692 /  17.21 

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

YCR = 2016 / 672 /  17.02 

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

YCR = 2016 / 694 /  17.00 

Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer

YCR = 2016 / 581 /  16.86 

The “cancer immunogram”

YCR = 2016 / 644 /  16.54 

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

YCR = 2016 / 539 /  16.35 

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

YCR = 2016 / 488 /  16.18 

PD-L1 expression in human cancers and its association with clinical outcomes

YCR = 2016 / 579 /  16.04 

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

YCR = 2016 / 600 /  16.02